Abstract:Full-length p53 (p53α) plays a pivotal role in maintaining genomic integrity and preventing tumor development. Over the years, p53 was found to exist in various isoforms, which are generated through alternative splicing, alternative initiation of translation, and internal ribosome entry site. p53 isoforms, either C-terminally altered or N-terminally truncated, exhibit distinct biological roles compared to p53α, and have significant implications for tumor development and therapy resistance. Due to a lack of part and/or complete C- or N-terminal domains, ectopic expression of some p53 isoforms failed to induce expression of canonical transcriptional targets of p53α like CDKN1A or MDM2 , even though they may bind their promoters. Yet, p53 isoforms like Δ40p53α still activate subsets of targets including MDM2 and BAX . Furthermore, certain p53 isoforms transactivate even novel targets compared to p53α. More recently, non-canonical functions of p53α in DNA repair and of different isoforms in DNA replication unrelated to transcriptional activities were discovered, amplifying the potential of p53 as a master regulator of physiological and tumor suppressor functions in human cells. Both regarding canonical and non-canonical functions, alternative p53 isoforms frequently exert dominant negative effects on p53α and its partners, which is modified by the relative isoform levels. Underlying mechanisms include hetero-oligomerization, changes in subcellular localization, and aggregation. These processes ultimately influence the net activities of p53α and give rise to diverse cellular outcomes. Biological roles of p53 isoforms have implications for tumor development and cancer therapy resistance. Dysregulated expression of isoforms has been observed in various cancer types and is associated with different clinical outcomes. In conclusion, p53 isoforms have expanded our understanding of the complex regulatory network involving p53 in tumors. Unraveling the mechanisms underlying the biological roles of p53 isoforms provides new avenues for studies aiming at a better understanding of tumor development and developing therapeutic interventions to overcome resistance.

The structure and function of p63 gene

A double dealing tale of p63: an oncogene or a tumor suppressor

P63 in health and cancer

Gene regulatory mechanisms orchestrated by p63 in epithelial development and related disorders

Molecular and Cellular Function of p63 in Skin Development and Genetic Diseases

Pathway Regulation of p63, a Director of Epithelial Cell Fate

Master regulatory role of p63 in epidermal development and disease

p63: a crucial player in epithelial stemness regulation

Functional Diversity of P53 in Human and Wild Animals

Disease-related p63 DBD mutations impair DNA binding by distinct mechanisms and varying degree

Functions of P53 in Pluripotent Stem Cells

P53 Isoforms Can Regulate P53 Transcriptional Activity

A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer

p53 family in development.

[Advances on Mutant P53 Research].

TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and hierarchy

P53 and Its Isoforms in DNA Double-Stranded Break Repair

Identification and functional characterization of two new transcriptional variants of the human p63 gene

Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance

The Significance of the Expression of Gene P63 in Laryngeal Squamous Cell Carcinoma

p63, a key regulator of Ago2, links to the microRNA-144 cluster